This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Biotinylated Human EphB4 Protein, His Tag, ultra sensitivity (primary amine labeling)
catalog :
EP4-H8229
quantity :
25 ug, 200 ug
price :
290 USD, 1250 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
EP4-H8229
product name :
Biotinylated Human EphB4 Protein, His Tag, ultra sensitivity (primary amine labeling)
quantity :
25 ug, 200 ug
price :
290 USD, 1250 USD
quantity & price :
$290/25ug,$1250/200ug
target :
EphB4
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
MABSol® Biotinylated Human EphB4, His Tag, primary amine labeling (EP4-H8229) is expressed from human HEK293 cells. It contains AA Leu 16 - Ala 539 (Accession # NP_004435.3). It is the biotinylated form of Human EphB4, His Tag (EP4-H5229).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>97% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Biotinylated Human EphB4, His Tag, primary amine labeling on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 97%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Ephrin type-B receptor 4(EPHB4) is also known as HTK, MYK1 and TYRO11,is a member of Eph family. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. The protein encoded by EPHB4 binds to Ephrin-B2 and plays an essential role in vascular development. EPHB4 and its ligand ephrin-B2 are specifically expressed on venous and arterial endothelial cells, respectively, and play an essential role in vascular development via bidirectional signals. The forward EPHB4 signaling inhibits cell adhesion, chemotaxis, angiogenesis and tumor growth. Incontrast, the reverse Ephrin-B2 signaling exerts the opposite effect. It has been reported that aberrant expression of EPHB4 is associated with prostate cancer and highly malignant breast cancers, accordingly, EPHB4 has potential application as a therapeutic candidate.
References :
(1) Bennett, B.D. et al., 1994, J. Biol. Chem. 269: 14211-14218.
(2) Noren, N.K. et al., 2006, Nat. Cell. Biol. 8: 815-825.
(3) Xia, G. et al., 2005, Cancer Res. 65: 4623-4632.
(4) Kertesz, N. et al., 2006, Blood. 107: 2330-2338.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments